摘要
目的评价国内美罗华联合CHOP方案化疗对非霍奇金淋巴瘤的疗效。方法应用国际Cochrane协作网的系统评价方法,经计算机检索,纳入美罗华联合CHOP方案治疗B细胞性非霍奇金淋巴瘤的随机对照试验。评价纳入研究的质量,并进行资料提取后,采用RevMan 4.2软件进行Meta分析。结果共纳入7篇文献,包括357例患者,文献间具有同质性,采用固定效应模型,结果:OR=3.02,95%CI(1.94,4.72)。美罗华联合CHOP方案治疗组与单纯CHOP方案对照组的完全缓解率比较,差异有统计学意义(P<0.01)。结论目前国内美罗华联合CHOP方案化疗对非霍奇金淋巴瘤有一定疗效,但由于纳入研究样本量小且质量较低,上述结论尚需要高质量、大样本的随机双盲对照试验加以证实。
Objective To evaluate the curative effect of Rituxmiab combined with CHOP chemotherapy on non-Hodgkin Lymphoma in China.Methods Systematic review method of ＂The Cochrane Collaboration＂ was used to collect,by computer retrieves,randomized controlled trials of Rituximab combined with CHOP for non-Hodgkin Lymphoma.The methodological quality of the included studies was evaluated,and data analyses were performed using Rev Man 4.2 software.Results A total of 7 literatures were enrolled,including 357 patients.There was homogeneity among all literatures,using fixed effect model,OR=3.02,95%CI（1.94,4.72）.There was significant difference in complete remission rate between combined CHOP group and single-used CHOP protocol group（P0.01）.Conclusion So far,domestic protocol of combined rituximab and CHOP chemotherapy is of some curative effects on non-Hodgkin lymphoma.But due to small and low-quality samples,large and high-quality samples are needed to confirm the above conclusions.
出处
《中国全科医学》
CAS
CSCD
北大核心
2011年第12期1331-1333,共3页
Chinese General Practice
